Related Experiment Video
Updated: Aug 12, 2025

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
Published on: May 7, 2020
[Analysis of 4 children with DYNC1H1 gene related spinal muscular atrophy with lower extremity predominant 1]
1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China.
Insights
Spinal muscular atrophy with lower extremity predominant 1 (SMALED1) in children is linked to DYNC1H1 gene variations. Early diagnosis and genetic testing are crucial for identifying this rare condition.
Area of Science:
- Genetics
- Neurology
- Pediatrics
Context:
- Spinal muscular atrophy with lower extremity predominant 1 (SMALED1) is a rare neuromuscular disorder.
- DYNC1H1 gene mutations are implicated in SMALED1.
- Understanding genotype-phenotype correlations is essential for diagnosis.
Purpose:
- To investigate clinical features and genetic variations in children with DYNC1H1-associated SMALED1.
- To analyze phenotype and genotype characteristics of SMALED1 patients.
- To identify novel DYNC1H1 gene variations.
Summary:
- Four children with SMALED1 were studied, all exhibiting lower limb muscle weakness and atrophy.
- Clinical manifestations included foot deformities, joint contractures, hip dislocation, and developmental delay.
- All patients had de novo heterozygous missense variations in the DYNC1H1 gene, including one novel variation.
Impact:
- Highlights the importance of considering DYNC1H1 gene testing in children with unexplained lower limb weakness and related symptoms.
- Aids in earlier diagnosis and potential management strategies for SMALED1.
- Contributes to the understanding of DYNC1H1-related disorders.
Abstract:
Objective: To investigate the clinical features and gene variation characteristics of children with dynein cytoplasmic 1 heavy chain 1 (DYNC1H1) gene associated spinal muscular atrophy with lower extremity predominant (SMALED) 1. Methods: The clinical data of 4 SMALED1 children admitted to Peking University First Hospital from December 2018 to May 2021, who were found to have pathogenic variation of DYNC1H1 gene through genetic testing, except for other genes known to be related to motor retardation, were retrospectively summarized to analyze the phenotype and genotype characteristics. Results: There were 3 males and 1 female. The age of onset was 1 year, 1 day, 1 day and 4 months, respectively. The age of diagnosis was 4 years and 10 months, 9 months, 5 years and 9 months, and 3 years and 1 month, respectively. The clinical manifestations were muscle weakness and muscular atrophy of lower limbs, 2 cases with foot deformity, 1 case with early non progressive joint contracture, 1 case with hip dislocation and 1 case with mental retardation. De novo heterozygous missense variations in DYNC1H1 gene were found in all 4 children. According to the rating of American College of medical genetics and genomics, they were all possible pathogenic and pathogenic variations, with p.R598C, p.P776L, p.Y1109D variations had been reported, and p.I1086R variation had not been reported. Conclusions: For those with unexplained lower limb muscle weakness, muscle atrophy, joint contracture and foot deformity, upper limb motor ability related retention, with or without mental retardation, as well as the motor ability progresses slowly, it is necessary to consider the possibility of SMALED1 and the detection of DYNC1H1 gene when necessary.
More Related Videos
06:52Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020